Dihydroxyphosphinecarboxylic acid oxide
Dihydroxyphosphinecarboxylic acid oxide Brand names, Dihydroxyphosphinecarboxylic acid oxide Analogs
Dihydroxyphosphinecarboxylic acid oxide Brand Names Mixture
- No information avaliable
Dihydroxyphosphinecarboxylic acid oxide Chemical_Formula
CH3O5P
Dihydroxyphosphinecarboxylic acid oxide RX_link
http://www.rxlist.com/cgi/generic2/foscarnet.htm
Dihydroxyphosphinecarboxylic acid oxide fda sheet
Dihydroxyphosphinecarboxylic acid oxide msds (material safety sheet)
Dihydroxyphosphinecarboxylic acid oxide Synthesis Reference
Noren, Jan O.; et al., J.Med.Chem. 26(2) 264-270(1983)
Dihydroxyphosphinecarboxylic acid oxide Molecular Weight
126.005 g/mol
Dihydroxyphosphinecarboxylic acid oxide Melting Point
88.06 oC
Dihydroxyphosphinecarboxylic acid oxide H2O Solubility
Complete
Dihydroxyphosphinecarboxylic acid oxide State
Solid
Dihydroxyphosphinecarboxylic acid oxide LogP
No information avaliable
Dihydroxyphosphinecarboxylic acid oxide Dosage Forms
Injection
Dihydroxyphosphinecarboxylic acid oxide Indication
For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
Dihydroxyphosphinecarboxylic acid oxide Pharmacology
Foscarnet is an organic analogue of inorganic pyrophosphate that inhibits replication of herpes viruses in vitro including cytomegalovirus (CMV) and herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Foscarnet does not require activation (phosphorylation) by thymidine kinase or other kinases and therefore is active in vitro against HSV TK deficient mutants and CMV UL97 mutants. Thus, HSV strains resistant to acyclovir or CMV strains resistant to ganciclovir may be sensitive to foscarnet. However, acyclovir or ganciclovir resistant mutants with alterations in the viral DNA polymerase may be resistant to foscarnet and may not respond to therapy with foscarnet. The combination of foscarnet and ganciclovir has been shown to have enhanced activity in vitro.
Dihydroxyphosphinecarboxylic acid oxide Absorption
Poorly absorbed after oral administration (bioavailability from 12 to 22%).
Dihydroxyphosphinecarboxylic acid oxide side effects and Toxicity
Oral, rat LD50: >2,000 mg/kg. Signs of overdose include renal impairment.
Dihydroxyphosphinecarboxylic acid oxide Patient Information
Dihydroxyphosphinecarboxylic acid oxide Organisms Affected
Human herpes viruses
